Division of Urology, Department of Surgery, National Yang-Ming Chiao Tung University Hospital, Yilan, Taiwan, R.O.C.
Department of Radiation Oncology, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
In Vivo. 2024 May-Jun;38(3):1079-1093. doi: 10.21873/invivo.13542.
BACKGROUND/AIM: In hepatocellular carcinoma (HCC) treatment, radiotherapy (RT) stands as a pivotal approach, yet the emergence of radioresistance poses a formidable challenge. This study aimed to explore the potential synergy between quetiapine and RT for HCC treatment.
A Hep3B xenograft mouse model was used, the investigation tracked tumor progression, safety parameters, and molecular mechanisms.
The findings revealed a synergistic anti-HCC effect when quetiapine was coupled with RT that prolonged tumor growth time and a significantly higher growth inhibition rate compared to the control group. Safety assessments indicated minimal pathological changes, suggesting potential of quetiapine in mitigating RT-induced alterations in liver and kidney functions. Mechanistically, the combination suppressed metastasis and angiogenesis-related proteins, while triggering the activation of apoptosis-related proteins via targeting Epidermal growth factor receptor (EGFR)-mediated signaling.
The potential of the quetiapine and RT combination is emphasized, offering enhanced anti-HCC efficacy, a safety profile, and positioning quetiapine as a radiosensitizer for HCC treatment.
背景/目的:在肝细胞癌(HCC)治疗中,放射治疗(RT)是一种重要的方法,但出现放射抗性是一个巨大的挑战。本研究旨在探讨喹硫平与 RT 联合治疗 HCC 的潜在协同作用。
使用 Hep3B 异种移植小鼠模型,研究跟踪肿瘤进展、安全性参数和分子机制。
研究结果显示,喹硫平与 RT 联合使用具有协同抗 HCC 作用,可延长肿瘤生长时间,与对照组相比,生长抑制率显著提高。安全性评估表明,病理变化最小,提示喹硫平有可能减轻 RT 引起的肝肾功能改变。机制上,该联合抑制转移和血管生成相关蛋白,同时通过靶向表皮生长因子受体(EGFR)介导的信号转导,触发凋亡相关蛋白的激活。
强调了喹硫平与 RT 联合应用的潜力,具有增强的抗 HCC 疗效、安全性,并将喹硫平定位为 HCC 治疗的放射增敏剂。